European thyroid journal · 2025
MAPK13 promotes the progression of papillary thyroid cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Runyu, Su Ziqi, Wan Zhihan, Qiao Peipei, Lu Yingying, Chi Yongbin, Zheng Liying, Zhang Yi, Huang Shuixian, Chen Xiaoping
Аннотация
OBJECTIVE: This study aims to analyze the genes that influence PTC progression and investigate the role of MAPK13 in PTC.
METHODS: Differentially expressed genes (DEGs) in Gene Expression Omnibus (GEO): GSE3467, GSE3678, GSE33630, and GSE58545 were analyzed between PTC and normal thyroid tissues. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) Cox regression analyses were performed on the DEGs using The Cancer Genome Atlas (TGCA) Program data. MAPK13 was subsequently identified as promoting progression in PTC. The association between MAPK13 expression and clinicopathological features was analyzed using data from public database and the collected cohort. The CCK-8 assay, EdU assay, wound healing assay, transwell assay, flow cytometry, GSEA enrichment analysis, and xenograft model were used to investigate the function of MAPK13 in PTC.
RESULTS: Higher expression of MAPK13 was associated with poorer progression-free survival, higher tumor pathologic stage, extrathyroidal extension, lymph node metastasis, multifocal tumors, American Thyroid Association (ATA) stratification system level, and BRAF V600E mutation. Overexpression of MAPK13 significantly promoted cell proliferation, migration, and invasion, and inhibited apoptosis of PTC. Knockdown of MAPK13 significantly inhibited cell proliferation, migration, and invasion, and promoted apoptosis of PTC. Epithelial-mesenchymal transition (EMT) was significantly enriched in GSEA analysis. Higher MAPK13 expression was related to higher N-cadherin and lower E-cadherin expression. Knockdown of MAPK13 significantly prevented tumor growth in vivo.
CONCLUSION: MAPK13 promotes the malignant biological behavior of PTC cells and is associated with EMT. MAPK13 may be a potential biomarker for treatment.
METHODS: Differentially expressed genes (DEGs) in Gene Expression Omnibus (GEO): GSE3467, GSE3678, GSE33630, and GSE58545 were analyzed between PTC and normal thyroid tissues. Univariate Cox regression and least absolute shrinkage and selection operator (LASSO) Cox regression analyses were performed on the DEGs using The Cancer Genome Atlas (TGCA) Program data. MAPK13 was subsequently identified as promoting progression in PTC. The association between MAPK13 expression and clinicopathological features was analyzed using data from public database and the collected cohort. The CCK-8 assay, EdU assay, wound healing assay, transwell assay, flow cytometry, GSEA enrichment analysis, and xenograft model were used to investigate the function of MAPK13 in PTC.
RESULTS: Higher expression of MAPK13 was associated with poorer progression-free survival, higher tumor pathologic stage, extrathyroidal extension, lymph node metastasis, multifocal tumors, American Thyroid Association (ATA) stratification system level, and BRAF V600E mutation. Overexpression of MAPK13 significantly promoted cell proliferation, migration, and invasion, and inhibited apoptosis of PTC. Knockdown of MAPK13 significantly inhibited cell proliferation, migration, and invasion, and promoted apoptosis of PTC. Epithelial-mesenchymal transition (EMT) was significantly enriched in GSEA analysis. Higher MAPK13 expression was related to higher N-cadherin and lower E-cadherin expression. Knockdown of MAPK13 significantly prevented tumor growth in vivo.
CONCLUSION: MAPK13 promotes the malignant biological behavior of PTC cells and is associated with EMT. MAPK13 may be a potential biomarker for treatment.